Altar M. Munis
PhD, BSc (Hons)
Postdoctoral Research Scientist
Funded by the Wellcome Trust, I am working on the development and optimisation of lentiviral gene therapy for lung diseases. In particular, my current project focuses on the treatment of surfactant protein B deficiency, a fatal autosomal recessive genetic disorder, using Sendai virus F/HN pseudotyped vectors.
Prior to joining the Gene Medicine group, I undertook my doctoral studies in gene therapy and immunology at University College London investigating the properties of phylogenetically distinct vesiculovirus glycoproteins that may have advantages over the prototypical glycoprotein from VSV Indiana strain.
Use of Heterologous Vesiculovirus G Proteins Circumvents the Humoral Anti-envelope Immunity in Lentivector-Based In Vivo Gene Delivery
Munis AM. et al, (2019), Molecular Therapy - Nucleic Acids, 17, 126 - 137
Lentivector Producer Cell Lines with Stably Expressed Vesiculovirus Envelopes.
Tijani M. et al, (2018), Mol Ther Methods Clin Dev, 10, 303 - 312
Characterization of Antibody Interactions with the G Protein of Vesicular Stomatitis Virus Indiana Strain and Other Vesiculovirus G Proteins
Munis AM. et al, (2018), Journal of Virology, 92